HLS Therapeutics Announces Q2 2018 Financial Results
(WorldNews Canada)

Revenue of $16.3 million, Net Loss of $0.6 millionand Adjusted EBITDA of $11.0 million, which were all in line with expectations Debt refinancing co-led by JPMorgan Chase Bank, N.A. and Silicon Valley Bank; interest savings estimated at $10.0 millionper year Establishment of a dividend policy providing for payment of quarterly dividends of CDN$0.05per common share and declaration of initial quarterly dividend of CDN$0.05per common share TORONTO, Aug. 15, 2018/CNW/ - HLS Therapeutics Inc. (`HLS` or the `Company`) (TSX-V: HLS), a specialty pharmaceutical company specializing in Central Nervous System (`CNS`) and Cardiovascular markets, announces its financial results for the three- and...